Bile Acid Sequestrants

Clinical Lipidology: A Companion to Braunwald's Heart Disease

Volumn , Issue , 2009, Pages 281-287

  Guyton, John R ^a   Goldberg, Anne Carol ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855495676     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141605469-6.50027-5     Document Type: Chapter

References (76)

1. Bergen SS, Van Itallie TB, Tennent DM, Sebrell WH Effect of an anion exchange resin on serum cholesterol in man. Proc Soc Exp Biol Med 1959, 102:676-679.
2. Effects of cholestyramine a bile acid sequestering exchange resin. Nutr Rev 1961, 19:292-293.
3. Hashim SA, Bergen SS, Van Itallie TB Experimental steatorrhea induced in man by bile acid sequestrant. Proc Soc Exp Biol Med 1961, 106:173-175.
4. Levy RI, Brensike JF, Epstein SE, et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: Results of the NHLBI Type II Coronary Intervention Study. Circulation 1984, 69:325-337.
5. Research Clinics Program Lipid The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984, 251:351-374.
6. Heel RC, Brogden RN, Pakes GE, et al. Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia. Drugs 1980, 19:161-180.
7. Glueck CJ, Ford S, Scheel D, Steiner P Colestipol and cholestyramine resin. Comparative effects in familial type II hyperlipoproteinemia. JAMA 1972, 222:676-681.
8. Kawashiri MA, Higashikata T, Nohara A, et al. Efficacy of colestimide coadministered with atorvastatin in Japanese patients with heterozygous familial hypercholesterolemia (FH). Circ J 2005, 69:515-520.
9. Colestimide. . Accessed 11-17-2007 . http://ClinicalTrials.gov.
10. Hofmann AF The enterohepatic circulation of bile acids in health and disease. Pathophysiology, Diagnosis, and Management 1983, 225-229. Philadelphia, Saunders. 3rd ed. M.H. Sleisinger, J.S. Fordtran (Eds.).
11. Love MW, Dawson PA New insights into bile acid transport. Curr Opin Lipidol 1998, 9:225-229.
12. Johns WH, Bates TR Quantification of the binding tendencies of cholestyramine. II. Mechanism of interaction with bile salt and fatty acid salt anions. J Pharm Sci 1970, 59:329-333.
13. Claudel T, Staels B, Kuipers F The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 2005, 25:2020-2030.
14. Grundy SM Cholesterol metabolism in man. West J Med 1978, 128:13-25.
15. Grundy SM, Ahrens EH Measurements of cholesterol turnover, synthesis, and absorption in man, carried out by isotope kinetic and sterol balance methods. J Lipid Res 1969, 10:91-107.
16. Grundy SM Treatment of hypercholesterolemia by interference with bile acid metabolism. Arch Intern Med 1972, 130:638-648.
17. Goodman DS, Noble RP, Dell RB The effects of colestipol resin and of colestipol plus clofibrate on the turnover of plasma cholesterol in man. J Clin Invest 1973, 52:2646-2655.
18. Schneider DL, Gallo DG, Sarett HP Effect of cholestyramine on cholesterol metabolism in young adult swine. Proc Soc Exp Biol Med 1966, 121:1244-1248.
19. Moutafis CD, Myant NB Increased hepatic synthesis of cholesterol after ileal by-pass in monkeys. Clin Sci 1968, 34:541-548.
20. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999, 284:1362-1365.
21. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999, 284:1365-1368.
22. Edwards PA, Kast HR, Anisfeld AM BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J Lipid Res 2002, 43:2-12.
23. Lee FY, Lee H, Hubbert ML, et al. FXR, a multipurpose nuclear receptor. Trends Biochem Sci 2006, 31:572-580.
24. Yabe D, Brown MS, Goldstein JL Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins. Proc Natl Acad Sci USA 2002, 99:12753-12758.
25. Shepherd J, Packard CJ, Bicker S, et al. Effect of cholestyramine on low-density lipoproteins. N Engl J Med 1980, 303:943-944.
26. Inagaki T, Moschetta A, Lee YK, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA 2006, 103:3920-3925.
27. Booker ML S-8921 (Shionogi). Curr Opin Investig Drugs 2001, 2:393-395.
28. Telford DE, Edwards JY, Lipson SM, et al. Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB. J Lipid Res 2003, 44:943-952.
29. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med 1990, 323:946-955.
30. Hofmann AF The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999, 159:2647-2658.
31. Mekjian HS, Phillips SF, Hofmann AF Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. J Clin Invest 1971, 50:1569-1577.
32. Oelkers P, Kirby LC, Heubi JE, Dawson PA Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene. (SLC10A2). J Clin Invest 1997, 99:1880-1887.
33. Staels B, Kuipers F Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 2007, 67:1383-1392.
34. Garg A, Grundy SM Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994, 121:416-422.
35. Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007, 29:74-83.
36. Commerford SR, Vargas L, Dorfman SE, et al. Dissection of the insulin-sensitizing effect of liver X receptor ligands. Mol Endocrinol 2007, 21:3002-3012.
37. Tomlinson E, Fu L, John L, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002, 143:1741-1747.
38. Insull W Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006, 99:257-273.
39. Adridge MA, Ito MK Colesevelam hydrochloride: A novel bile acid-binding resin. Ann Pharmacother 2001, 35:898-907.
40. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (Cholestagel). A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999, 159:1893-1900.
41. Hunninghake DB, Bell C, Olson L Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemia. Metabolism 1981, 30:610-615.
42. Hunninghake DB, Probstfield JL, Crow LO, et al. Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia. Metabolism 1981, 30:605-609.
43. Insull W, Toth P, Mullican W, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: A 24-week randomized controlled trial. Mayo Clin Proc 2001, 76:971-982.
44. Research Clinics Program Lipid The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984, 251:365-374.
45. Lyons D, Webster J, Fowler G, et al. Colestipol at varying dosage intervals in the treatment of moderate hypercholesterolemia. Br J Clin Pharmac 1994, 37:59-62.
46. Insull W, Davidson MH, Demke DM, et al. The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. Atherosclerosis 1995, 112:223-235.
47. Vecchio TJ, Linden CV, O'Connell JMJ, et al. Comparative efficacy of colestipol and clofibrate in type IIa hyperlipoproteinemia. Arch Intern Med 1982, 142:721-723.
48. Research Clinics Program Lipid The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984, 251:365-374.
49. Davidson MH, Toth P, Weiss S, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol 2001, 24:467-474.
50. Hunninghake D, Insull W, Toth P, et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001, 158:407-416.
51. Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001, 110:352-360.
52. Pan HY, DeVault AR, Swites BJ, et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther 1990, 48:201-207.
53. Denke MA, Grundy SM Efficacy of low-dose cholesterol-lowering drug therapy in men with moderate hypercholesterolemia. Arch Intern Med 1995, 155:393-399.
54. Davidson MH, Dicklin MR, Maki KC, Kleinpell RM Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent. Exp Opin Invest Drugs 2000, 9:2663-2671.
55. Malloy MJ, Kane JP, Kunitake ST Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. Ann Intern Med 1987, 107:616-623.
56. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987, 257:3233-3240.
57. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289-1298.
58. Bays H, Rhyne J, Abby S, et al. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin 2006, 22:2191-2200.
59. McKenny J, Jones M, Abby S Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin 2005, 21:1403-1412.
60. Bays HE, Davidson M, Jones MR, Abby SL Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006, 97:1198-1205.
61. Devaraj S, Autret B, Jialal I Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia. Am J Cardiol 2006, 98:641-643.
62. Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992, 339:563-569.
63. Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990, 264:3007-3012.
64. Physicians Desk Reference. Physicians Desk Reference 2005, 2978-2979. Thomson PDR, Montvale, NJ.
65. Antons KA, Williams CD, Baker SK, Phillips PS Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006, 119:400-409.
66. Stone NJ, Blum CB. Management of Lipids in Clinical Practice, 5th ed. Caddo, OK, Professional Communications. 2005:284-289.
67. Colestid (colestipol) product information. Physicians Desk Reference. Montvale, NJ, Thomson PDR 2004, pp 2740-2742.
68. Spence JD, Huff MW, Heidenheim P, et al. Combination therapy with colestipol and psyllium mucilloid in patients with hyperlipidemia. Ann Intern Med 1995, 123:493-499.
69. Abraczinskas D, Goldfinger SE Intestinal gas and bloating. UpToDate 2007, Waltham, MA. B.D. Rose (Ed.).
70. Adult Treatment Panel III: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Bethesda, MD, NIH Publication No. 02-5215, National Institutes of Health 2002, vi-9-vi-10.
71. Crouse JR Hypertriglyceridemia: A contraindication to the use of bile acid binding resins. Am J Med 1987, 83:243-248.
72. Witztum JL, Schonfeld G, Weidman SW, et al. Bile sequestrant therapy alters the compositions of low-density and high-density lipoproteins. Metabolism 1979, 28:221-229.
73. West RJ, Lloyd JK The effect of cholestyramine on intestinal absorption. Gut 1975, 16:93-98.
74. Schwarz KB, Goldstein PD, Witztum JL, Schonfeld G Fat-soluble vitamin concentrations in hypercholesterolemic children treated with colestipol. Pediatrics 1980, 65:243-250.
75. Hoogwerf BJ, Hibbard DM, Hunninghake DB Effects of long-term cholestyramine administration on vitamin D and parathormone levels in middle-aged men with hypercholesterolemia. J Lab Clin Med 1992, 119:407-411.
76. Vroonhof K, van Rijn HJ, van Hattum J Vitamin K deficiency and bleeding after long-term use of cholestyramine. Neth J Med 2003, 61:19-21.